# A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

> **NCT02158091** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** IPI-145
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02158091
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-06-27
- **Primary completion:** 2017-10
- **Final completion:** 2026-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158091, "A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02158091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*